From Mobile Clinics to Drug Development, This Company Is Attempting to Tackle Brain Disorders and Promote Mental Health Advances

Photo by David Matos on Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Pasithea Therapeutics Corp. KTTA, a biotech company dedicated to the research and development of therapies for treating psychiatric and neurological disorders, has recently been reporting about its mobile clinics that offer ketamine-infusion therapy to improve the symptoms of certain mental health disorders.

Pasithea Clinics have been rolled out in major cities across the U.K. and the U.S., including London, New York City, Los Angeles, San Diego and San Francisco. It also announced recent expansions into Florida and Nevada.

Pasithea Clinics hopes to enable patients to receive ketamine therapy that can alleviate the symptoms of certain brain disorders such as depression and post-traumatic stress disorder. Pasithea Clinics allows treatment to occur within the privacy and comfort of patients’ own homes and with the benefit of personalized care from experienced medical staff. Pasithea Clinics is also currently one of only three accredited clinics in the U.K. approved to offer esketamine nasal spray (SPRAVATO®) for treatment of mental health disorders.

Nevertheless, these clinics reportedly constitute only one component of Pasithea’s overall business model. Pasithea is also focused on developing new treatments for brain disorders.

Pasithea says its approach combines immunology and neuroscience developments to harness new therapeutics for psychiatric and neurologic diseases — especially in people who have been traditionally underserved.

Most recently, Pasithea announced its latest initiative of a new chemical entity (NCE) development program with Evotec A.G. EVO as its research partner. 

Other companies in the sector include ABVC Biopharma Inc. ABVC and ANI Pharmaceuticals Inc. ANIP. However, one of Pasithea’s goals is to distinguish itself by maintaining a specialized focus on mental health and brain disorders. 

To learn more about Pasithea’s ongoing therapeutic solutions, latest developments and investor information, visit the company website here. 

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.